Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Diseases 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1

Interventions

Injections 12pembrolizumab 7toripalimab 5tislelizumab 5Oxaliplatin 3Gemcitabine 3Cisplatin 3Carboplatin 3trastuzumab deruxtecan 2spartalizumab 2lenvatinib 2atezolizumab 2Paclitaxel 2Nivolumab 2Immune Checkpoint Inhibitors 2Fulvestrant 2Fluorouracil 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2zimberelimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1fludarabine phosphate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumor × penpulimab × Clear all
NCT06825494 2025-12-18

Clinical Studies for the Treatment of Advanced Solid Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
194 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡